// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

Disease and Treatment Characteristics that Might Influence Long-term Retention with Biologics in the Real-world Clinical Setting: Experience from the Rhumadata Clinical Database and Registry

Louis Bessette - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Adalimumab

A Retrospective Cohort of Aortitis Cases in Calgary Over 10 Years

Aurore Fifi-Mah - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Aortic wall inflammation

N/A

Six Years Tocilizumab Use in Patients with Rheumatoid Arthritis with One Previous AntiTNF Agent Exposure: Comparison with Adalimumab and Etanercept from the Provincial Electronic Database and Registry Rhumadata

Denis Choquette - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Tocilizumab

Novel Biomarkers Identified by Quantitative Mass Spectrometry Differentiate Patients with Psoriatic Arthritis (PsA) from Patients with Psoriasis without PsA

Daniela Cretu - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriatic arthritis

N/A

Temporomandibular Pain in Patients with Juvenile Idiopathic Arthritis.

Marinka Twilt - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Six-Year Retention Rates with Abatacept vs TNF inhibitors in the Treatment of Rheumatoid Arthritis: Experience from the Real-world Rhumadata Clinical Database and Registry

Louis Bessette - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Adalimumab

Use of Rituximab Compared to Anti-TNF Agents as Second and Third Line Therapy in Patients with Rheumatoid Arthritis. A 6 Year Follow-Up Report from the Rhumadata Clinical Database and Registry

Denis Choquette - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Adalimumab

Update on Rituximab Induction in Relapsing Granulomatosis with Polyangiitis (GPA): Long-term Outcome 12 Years Post-treatment

Elaine Yacyshyn - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Wegener's granulomatosis

Filgrastim

Key Performance Indicators for Evaluation of Centralized Intake Systems for Osteoarthritis and Rheumatoid Arthritis Healthcare Teams in Alberta

Jatin Patel - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Rheumatoid arthritis

N/A

Measuring the Rheumatologist Workforce in Canada: Stand Up and Be Counted!

Lauren Jewett - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

PAN versus MPA: A Case Dilemma

Elaine Yacyshyn - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Polyarteritis nodosa

N/A

Using Serum-based Soluble Markers to Differentiate Psoriatic Arthritis from Osteoarthritis

Anthony Perruccio - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriatic arthritis

Hyaluronic acid

A Systematic Review of Rheumatoid Arthritis Characteristics and Clinical Outcomes in Indigenous Populations of Canada, the United States, Australia and New Zealand

Cheryl Barnabe - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Patient Preferences in Decision Making for Treatment of Rheumatoid Arthritis: A Systematic Review

Caylib Durand - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Paraneoplastic Digital Gangrene: A Case Report and Review of the Literature

Daniel Ennis - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Endometrial Cancer

N/A

Cardiovascular Disease in the Canadian Early Arthritis Cohort

Janet Pope - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Peripheral artery disease

N/A

Predictors of Long-Term Retention of Anti-TNF Treatment: An Analysis from a Prospective, Observational Registry.

Philip Baer - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ankylosing spondylitis

Infliximab

Cardiovascular Comorbidity in SLE has a Large Care Gap

Janet Pope - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Hypertension

Methadone hydrochloride

Nurse-led Care for Patients with Rheumatoid Arthritis: A Systematic Review

Deborah Marshall - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Increased Direct Healthcare Costs in Systemic Lupus Erythematosus Pregnancies

Sasha Bernatsky - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

Copyright © 2026. QuantiNova All rights reserved